Topics to include DNA and RNA profiling and next-generation sequencing of tumors SAN ANTONIO--(BUSINESS WIRE)--Dec. 3, 2018-- Significant developments in breast cancer research will be presented by NantHealth (NASDAQ: NH) at the San Antonio Breast Cancer Symposium this week. NantHealth, a leader in breakthrough cancer research and solutions to improve patient care and lower healthcare costs, will discuss the findings of three investigations, w...

Read More >

Total Revenue in Q3 was $22.3 Million SaaS revenue of $15.9 million in Q3, up 5% from $15.2 million in prior year Q3 Enhanced efficiencies continued to drive reduced operating expenses and improved adjusted bottom line results Sequencing and Molecular Analysis, 930 total tests ordered in Q3, including 461 GPS Cancer® and 469 Liquid GPS® Tests...

Read More >

--Slight Delay in Reporting Financial Results, Due to Effects of Hurricane Michael-- CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 7, 2018-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2018 third quarter on Thursday, November 15, 2018, after market close. NantHealth management will host a conference call that same day at 1:30 p....

Read More >